E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic obstructive pulmonary disease (bronchodilating effect) |
|
E.1.1.1 | Medical condition in easily understood language |
This is a progressive lung diseases including emphysema, chronic bronchitis, and non-reversible asthma. This disease is characterized by increasing breathlessness. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010952 |
E.1.2 | Term | COPD |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary Objective
- To assess the non-inferiority between Tiotropium DPI capsule 8.8μg and Spiriva® 18μg Handihaler® by measurement of the bronchodilating effect
|
|
E.2.2 | Secondary objectives of the trial |
• Secondary Objectives
- To assess and compare the safety of both products.
- To demonstrate a difference between the two dosages of SMB tiotropium
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
nclusion criteria
Patients must satisfy the following criteria before entering the study:
1. Male and non-pregnant female aged over 40 years old
2. Documented history of stable COPD with moderate to severe airflow obstruction diagnosed for more than six months according to the GOLD standard prior to the screening visit
3. FEV1 more than or equal to 30% and inferior to 80% of predicted at screening.
4. FEV1/FVC following 200 µg salbutamol treatment intake < 0.7 at screening.
5. Reversibility of at least 12% and 100 ml in FEV1 30-45 minutes after maximum 400 µg of salbutamol
6. Current smokers or history of ex-smokers (≥10 pack-year smoking history).
7. Able to comply with all study procedures, including the use of study inhalers and spirometer
8. Provide written informed consent to participate in the study, indicated by a personal signature and date on the patient consent form
|
|
E.4 | Principal exclusion criteria |
Exclusion criteria
Patients who meet any of the following criteria will be excluded from participating in the study:
1. Evidence of any unstable or untreated clinically significant immunological, cardiac, cardiovascular, neoplastic, endocrine, haematological, gastrointestinal, neurological or psychiatric abnormality or disease. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk during her/his participation, or which could affect the endpoint analysis if the disease/condition exacerbated during the study
2. Respiratory tract infection or COPD exacerbation not completely resolved within the last 2 weeks prior to the screening visit or between the screening and the randomization
3. Abnormality of inspiratory function (e.g. laryngeal obstruction, neuromuscular disease)
4. Need for daily oxygen therapy
5. Asthma, allergic rhinitis, cystic fibrosis, bronchiolitis obliterans, fibrosis, active or latent tuberculosis, α1-antitrypsin deficiency or any other causes of chronic airflow limitation apart from COPD
6. Use of any of the prohibited medications as detailed in the concomitant medication section
7. Patients with any sensitivity or allergy to any of the products used within this clinical trial
8. Female pregnant, breast-feeding or of childbearing potential age without efficient means of birth control (IUD, OCS, implants, hormonal patch, vaginal ring or spermicide and condom)
9. Patients with human immunodeficiency virus (HIV), Hepatitis B (HBV) or Hepatitis C (HCV)
10. Participation in any investigational medical studies within 2 month prior the screening visit
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint:
-Trough FEV1 response defined as change in FEV1 from baseline to FEV1 24h post-dose measurement
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Secondary parameters:
Efficacy endpoint:
- Peak bronchodilatory effect (FEV1 max)
- Tmax of FEV1
- Baseline-adjusted area under the curve (AUC) for FEV1 over 24 hours post dosing
- PEF max
- Baseline adjusted AUC of PEF from 0 to 24 hours post dosing
- Change in PEF at 24 hours post dose from baseline
- FEV1 % max
- Baseline adjusted AUC of FEV1% from 0 to 24 hours post dosing
- Change in FEV1% at 24 hours post dose from baseline
- FVC max
- Baseline adjusted AUC of FVC from 0 to 24 hours post dosing
- Change in FVC at 24 hours post dose from baseline
- Partial baseline adjusted AUC for FEV1 from 0 to 4 hours post dose
- Partial baseline adjusted AUC for FEV1 from 4 to 8 hours post dose
- Partial baseline adjusted AUC for FEV1 from 8 to 12 hours post dose
- Partial baseline adjusted AUC for FEV1 from 12 to 24 hours post dose
Safety endpoints:
- Adverse events
- Physical examination
- Vital signs
- 12-lead ECG data
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Visit 1-Visit 2-Visit 3-Visit 4 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 3 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |